FK506

Phase 3Small molecule

Astellas

FK506 is one of 166 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

KeratoconjunctivitisActive, not recruiting

Hematologic DiseaseActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Focal Segmental GlomerulosclerosisActive, not recruiting

Membranous NephropathyActive, not recruiting

Liver TransplantPreclinical

Active, not recruiting

KeratoconjunctivitisPhase 3

Active, not recruiting

Hematologic DiseasePhase 1/Phase 2

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Focal Segmental GlomerulosclerosisPreclinical

Active, not recruiting

Membranous NephropathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

353 competitors in Liver Transplant

#DrugCompanyPhaseTrials

FK506

Astellas

Phase 3

1 2

Vemlidy

Gilead

Preclinical

3 3

Cysteine Hydrochloride

Novartis

Preclinical

3 4

Octreotide

Johnson & Johnson

Preclinical

2 5

Lenvima

Eisai

Preclinical

2 6

Beyfortus

BeiGene

Preclinical

1 7

Myfortic

Novartis

Preclinical

1 8

Prostigmin

Merck & Co.

Preclinical

1 9

Myfortic

Novartis

Preclinical

6 10

Cyklokapron

AAmring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconjunctivitis2 trials

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Completed· Astellas logo

Astellas·Phase 3·NCT00567918·52 enrolled

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Completed· Astellas logo

Astellas·Phase 3·NCT00567762·56 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040417·15 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H

Terminated·—·Phase 1/2·NCT00048399·40 enrolled

Sickle Cell Disease1 trial

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00034528·2 enrolled

Focal Segmental Glomerulosclerosis1 trial

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Terminated·NNanjing University School of Medicine·N/A·NCT01451489·70 enrolled

6 more indications

Membranous Nephropathy1 trial

Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid

Completed·ZZhi-Hong Liu, M.D.·N/A·NCT01161459·100 enrolled

Allogeneic Stem Cell Transplantation1 trial

Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases

Terminated·—·Phase 1/2·NCT00056979·2 enrolled

Hematologic Disease1 trial

Stem Cell Transplant for Hematologic Diseases

Terminated·—·Phase 1/2·NCT00058825·27 enrolled

Liver Transplant1 trial

Investigation of Pain Incidence After FK506 Immunosuppressive Therapy in Liver Transplantation Patients

Unknown status·—··NCT04559048·300 enrolled

Efficacy and Safety1 trial

To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN

Completed·NNanjing University School of Medicine·N/A·NCT00302549·61 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Completed·—·Phase 1/2·NCT00056966·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for FK506. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FK506 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FK506. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Astellas

FK506

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconjunctivitis2 trials

Bone Marrow Transplant1 trial

Stem Cell Transplantation1 trial

Sickle Cell Disease1 trial

Focal Segmental Glomerulosclerosis1 trial

Membranous Nephropathy1 trial

Allogeneic Stem Cell Transplantation1 trial

Hematologic Disease1 trial

Liver Transplant1 trial

Efficacy and Safety1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News